Connect with us
Crown Laboratories is acquiring Revance Therapeutics to expand its presence in the beauty market, offering $6.66 per share, an 89% premium. Revance, maker of the Botox...
Teva's first-half performance in Spain exceeds annual forecasts, with 2024 growth projected at 7.5%. The company has invested over €70 million in Spain since 2008, with...
Eli Lilly's first-half 2023 revenues surged 31% to $20 billion, driven by Mounjaro's $4.9 billion in sales, dominating the company’s earnings. Trulicity, in contrast, saw a...
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...
In the first half of the year, Novo Nordisk saw significant growth in sales, with Ozempic revenue up 36% to 56.685 billion crowns (€7.596 billion) and...
BioNTech's revenues plummeted 78.1% in the first half of 2024, down to €316.3 million, due to decreased demand for Covid-19 vaccines and a seasonal sales lull....
According to the results presented by the pharmaceutical giants to the National Securities Commission (CNMV), the revenues of these five companies also rose in the first...
Córdoba Biotech Incubator specializes in biotechnology, offering three types of incubation: physical with labs, coworking, and virtual. It supports startups through tailored programs based on project...
Oryzon Genomics reported a loss of €2.4 million in the first half of 2024, slightly less than the €2.5 million loss in 2023. Financial losses decreased...
PharmaMar's turnover rose 0.8% in H1 2024, reaching €80.8 million, with oncology sales down 3.2%. Royalty income increased by 16%, while non-recurring income slightly declined. R&D...